Open Multicenter Study of Combination Therapy With Weight-Based PEG-IFN Alfa-2b [peginterferon-alfa-2b] Plus Ribavirin for Treatment of Mexican naive Patients With Chronic Hepatitis C Infected With Genotype 1. Impact of the Combination Therapy on Sustained Virological Response and Tolerability, in These Patients

Trial Profile

Open Multicenter Study of Combination Therapy With Weight-Based PEG-IFN Alfa-2b [peginterferon-alfa-2b] Plus Ribavirin for Treatment of Mexican naive Patients With Chronic Hepatitis C Infected With Genotype 1. Impact of the Combination Therapy on Sustained Virological Response and Tolerability, in These Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Aug 2008

At a glance

  • Drugs Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 18 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top